Abstract: Construction of gene-gene interaction networks and potential pathways is a challenging and important problem in genomic research for complex diseases while estimating the dynamic changes of the temporal correlations and non-stationarity are the keys in this process. In this paper, we develop dynamic state space models with hierarchical Bayesian settings to tackle this challenge for inferring the dynamic profiles and genetic networks associated with disease treatments. We treat both the stochastic transition matrix and the observation matrix time-variant and include temporal correlation structures in the covariance matrix estimations in the multivariate Bayesian state space models. The unevenly spaced short time courses with unseen time points are treated as hidden state variables. Hierarchical Bayesian approaches with various prior and hyper-prior models with Monte Carlo Markov Chain and Gibbs sampling algorithms are used to estimate the model parameters and the hidden state variables. We apply the proposed Hierarchical Bayesian state space models to multiple tissues (liver, skeletal muscle, and kidney) Affymetrix time course data sets following corticosteroid (CS) drug administration. Both simulation and real data analysis results show that the genomic changes over time and gene-gene interaction in response to CS treatment can be well captured by the proposed models. The proposed dynamic Hierarchical Bayesian state space modeling approaches could be expanded and applied to other large scale genomic data, such as next generation sequence (NGS) combined with real time and time varying electronic health record (EHR) for more comprehensive and robust systematic and network based analysis in order to transform big biomedical data into predictions and diagnostics for precision medicine and personalized healthcare with better decision making and patient outcomes.
Introduction
Progress in mapping the human genome and developments in array technologies have provided considerable amount of information for delineating the roles of genes in disease and treatment states (Collins et al., 2003; Tuzun et al., 2005; Gonzaga-Jauregui et al., 2012; McElheny, 2012; Snyder et al., 2012) . These advances provide a vision for a comprehensive genome analysis where individual gene functions are examined within the context of all the other genes in multiple tissues over time for broader biological understanding at molecular level and medical findings (Liang and Kelemen, 2006) . However, modeling a large amount of interactions among many genes, particularly over time, is one of the key challenges of the post-genomic era . Despite advances in the state of knowledge and considerable computational and statistical efforts over the past decade in this field, a critical issue of methodology challenge remains: how to make efficient and maximal use of the big genomic data in the presence of thousands of genes with accumulative small or moderate effects on disease and health conditions, the large number of interactions with the overwhelming number of confounded traits, time dependence and other complex structures simultaneously presented in addition to the unavoidable noises, and heterogeneities.
Time-course gene expression data are often measured to study dynamic biological systems since knowing when or whether a gene is differentially expressed over time, and how one interacts with others can provide a strong clue of its biological role that may have therapeutic implication (Hoon et al., 2002; Ramoni et al., 2002; Bar-Joseph et al., 2003; Ernst et al., 2005; Liang et al., 2005; Zou and Conzen, 2005; Osamu et al., 2008) . Affymetrix microarray data hold tremendous latent information that requires more sophisticated computational tools to tackle the hidden information (Almon et al., 2003a) . Clustering analyses are the most commonly used statistical methods due to the large number of genes involved and the identification of groups of genes with "similar" temporal patterns of expression is usually a critical step in the analysis of kinetic data (D'haeseleer et al., 2000; Holter et al., 2001; Gasch and Eisen, 2002; Ramoni et al., 2002; Ernst et al., 2005) . Conventional time series techniques, autoregressive or moving averaging models, dynamic Bayesian clustering approaches have been developed and applied (Durbin and Koopman, 2000; Ramoni et al., 2002) ; however, these methods require stationary conditions, linearity for lower order autoregressive models, and uniformly spaced time points, which are not present in time course microarray experiments following drug treatment (Almon et al., 2003a) . Some curve fitting, spline (e.g. in terms of polynomials in time) methods, mixed effects models, and nonlinear regression models have also been applied to temporal microarray data and they can model the nonlinear relations between genes, can deal with the unevenly time spaced data and may produce a good fit, but they do not include the natural time order information during the modeling process, and may cause over-fitting problems which do not support predictions (Wolfmger et al., 2001) .
Various network and pathway based computational approaches have been developed for modeling time course genomic data to infer and predict the dynamic profiles and gene-gene interactions (Friedman et al., 2000; Gilks and Berzuini, 2001; Kimm et al., 2002; Perrin et al., 2003; Friedman, 2004; Liang and Kelemen, 2004; Yu et al., 2004; Chen et al., 2005; Jones and West, 2005; Dojer et al., 2006; Carvalho and West, 2007; Carvalho et al., 2007a; Li et al., 2007; Shmulevich and Dougherty, 2009; Ghasemi et al., 2011; Grzegorczyk and Husmeier, 2011; Mitra et al., 2013; Peterson et al., 2014) . Probabilistic Boolean Networks were developed as models of gene regulatory networks and are able to cope with uncertainty and discover the relative sensitivity of genes in their interactions with other genes (Li et al., 2007; Shmulevich and Dougherty, 2009 ). Friedman et al. and a few others have developed static Bayesian networks, which are Gaussian graph based models of joint multivariate probability distributions that assess conditional independence between variables, to obtain simpler sub-models to describe gene interactions from array data (Friedman et al., 2000; Friedman, 2004) . Covariance decomposition methods and singular value decomposition have been applied for modeling the microarray data (Kimm et al., 2002) . The difficulties of these methods are the estimation of the dimensionality and ill-posed problems and computational inefficiency. Non-linear differential equation based approaches have been also applied to genetic, biochemical network data (Chen et al., 2005; Jones and West, 2005; Ghasemi et al., 2011) . For instance, Chen et al. developed a stochastic differential equation model for quantifying transcriptional regulatory network in Saccharomyces cerevisiae Jones and West). Kimm et al. developed an algorithm to identify interaction network and coupled with non-parametric regression methods (Chen et al., 2005) . Ghasemi et al. developed differential equations with a Bayesian method that can model linear and nonlinear dynamic changes in transcriptional levels (Ghasemi et al., 2011) . These existing models can potentially provide valuable quantitative and mechanistic descriptions of the time courses of gene expression mediated by drugs/ pharmacological agents (Nguyen et al., 2014) . However, these mathematical models have not incorporated the unevenly spaced short time course gene expressions with unseen time points, stochastic nature of genomic data, the time delay information; and they often treat the biological parameters as fixed values without probability and uncertainty involved in the estimations (Hazra et al., 2008; Fang et al., 2011) .
Considering the demerits of existing computational tools for gene-gene interaction and network analysis, the probability and confidence measures play important roles in genomic data not only due to the weak/small gene effects, high variations, high noise levels and experimental errors, but also the stochastic nature involved in the genetic process. The Bayesian paradigm is very well suited for examining these features and other properties in the genomic data, such as highly correlated inputs (genes, time points), missing data, and small sample size (West and Harrison, 1999; Baldi and Long, 2001; Efron et al., 2001; Gilks and Berzuini, 2001; Ibrahim et al., 2002; Troyanskaya et al., 2003; West, 2003; Beaumont and Rannala, 2004; Liang and Kelemen, 2004 , 2007 , 2008 Yu et al., 2004; Beal et al., 2005; Rogers and Girolami, 2005) . Computation of the posterior probability distribution is all that is required for making the desired inferences, such as the computation of credible intervals as alternative of false discovery rate (Storey, 2003) . Recently developed dynamic Bayesian networks and dynamic matrix-variate graphical models demonstrated promising results for genetic network constructions (Perrin et al., 2003; Dojer et al., 2006; Carvalho and West, 2007; Carvalho et al., 2007a; Grzegorczyk and Husmeier, 2011; Mitra et al., 2013; Peterson et al., 2014) . However, the majority of these existing Bayesian networks or graphic techniques still treat time as a discrete or categorical variable and not as a continuous variable. This distinction is important because the kinetic parameters derived from ordinal variables will not carry meaning except in the case where the time points are evenly spaced. This will not be the case for unevenly spaced short time course gene expression data following the drug treatment.
In our earlier studies, we have developed and applied univariate Bayesian state space model for modeling the temporal gene expression data, which have advantages of uniformly integrating the stochastic paradigm with the observation data to capture the change of gene states (Liang and Kelemen, 2007) . Stochastic paradigm treats the observation process of gene expression change as a stochastic process to describe the evolution of a probability genetic system in time. In this paper, multivariate Bayesian state space models are proposed and formulated for construction of the dynamic genetic networks that are significantly associated with drug therapy. In Section 2, multiple tissue Affymetrix data sets following corticosteroid (CS) drug therapy is provided. In Section 3, multivariate state space models and hierarchical Bayesian approaches are developed for dynamic genetic network constructions in order to capture linear, non-linear, combinatorial, and stochastic types of relationships among genes over time. MCMC algorithms are used to sample the posterior distribution of the hidden variables and estimate the model parameters. Various prior models with different hyper-prior distributions are simulated and compared, and deviance information criterion (DIC) is used for model comparisons and selections. The developed models are applied to multiple tissue Affymetrix data sets following CS drug administration, which are presented in Section 4. Conclusion and discussion is provided in Section 5.
Multiple tissue Affymetrix data sets following corticosteroid drug administration
CSs are a class of compounds that exhibit the most potent immunosuppressive and anti-inflammatory activities. These drugs are widely used in a variety of acute and chronic diseases, such as asthma, leukemia, and organ transplantation. Because drug activity requires a sequential series of events in order to elicit its effects, different genes may exhibit different expression profiles over time following the administration of a drug dose. The particular genes that are either up-regulated or down-regulated, in combination with specific dynamic changes, and their interactions may be predictive of the ultimate outcomes resulted from drug therapy (Almon et al., 2003a,b) . On the other hand, all systemic phenomena, such as blood pressure and glycemic control are phenomena that involve multiple genes in multiple tissues. Similarly, pathologies such as diabetes, hypertension, dyslipidemia, and arteriosclerosis caused by chronic CS treatment are complex phenomena involving altered expression of multiple genes in several tissues (Carter and Kohn, 1994) . Sites of particular importance to the development of such adverse effects include the liver, kidney, skeletal muscle, and adipose tissue. The majority of CS effects on these tissues are caused by induced changes in gene expression. These changes in gene expression can be direct where the drug receptor complex binds to a glucocorticoid response element (GRE) upstream of that gene and modulates its expression or may be indirect where the drug receptor complex induces the expression of a secondary biosignal [often-another transcription factor (TF)] that in turn modulates expression of that gene.
It is important to improve our understanding of the gene-gene interactions and time-dependent dynamic changes in gene expression caused by CS therapy in order to potentially discover the precise genes that may be the most critical in producing favorable therapeutic outcomes versus those that may instigate negative, unwanted effects. An interesting application of genetic network analysis is to investigate the dynamic changes and gene-gene interactions in response to the drug therapy in multiple-tissue polygenetic expression data. The experimental data applied in this paper is generated from a pre-clinical study performed on experimental rats. Forty-eight animals received a single IV bolus 50 mg/kg dose of methylprednisolone (MPL) (Almon et al., 2003b) . Liver, skeleton muscle, and kidney tissues are collected from each animal and processed to assay for gene expression. Three rats are consequently sacrificed at each of the following experimental uneven time points: 0. 25, 0.5, 0.75, 1, 2, 4, 5, 5.5, 6, 7, 8, 12, 18, 30, 48 , and 72 h. Therefore, triplicate measurements are obtained at each of these time points. Four rats are not administered any drug and were sacrificed at time t = 0. These serve as the control group for gene expression in the absence of any drug at baseline. Total RNA is separately extracted from the three tissue samples from each animal and purified. The isolated RNA is then used to create biotinylated cRNA. This target cRNA was hybridized to Affymetrix GeneChips Rat Genome U34A.
To determine expression measures of probe set from probe signals with lowest data variance and bias for the low-level analysis, probe set RMA and GCRMA algorithms are performed for background subtraction, signal intensity normalization between arrays, and non-specific hybridization correction. A series of preprocessing steps are performed in order to eliminate probe sets that were not expressed in the tissue due to MPL dosing, or did not meet defined quality control standards. A simple inverse of Coefficient of Variation test is utilized to test the variation in gene expression over time. The ratios of gene expressions between subsequent times with baseline are calculated and the base 2 logarithms computed for normalization. The significant differentially expressed genes from each tissue published in our earlier articles (Beal et al., 2005; Kelemen, 2008, 2009 ) using Bayesian finite Markov mixture model and meta-analysis are included in this study in order to demonstrate the proposed methods. In particular, six selected commonly differentially expressed genes in three tissues (kidney, liver and muscle) are examined first for gene-gene interaction network analysis and for predicting their dynamic changes in response to CS drug. Forty-four genes differentially expressed commonly in two tissues (liver and muscle) are then applied to further validate the proposed models for constructing gene interaction networks.
Methods

State space model formulation for genetic network construction
Gene expression measurements (observations) are contaminated by noise. A dynamic state space model decomposes the signal and noise processes into two model equations: hidden state variables defined in the stochastic transition (evolution) equation and observation variables defined in the statistical or observation equations. A sequence of P-dimensional real valued observation vector Y t of gene expression is then modeled by assuming that each time step, Y t are generated from a N-dimensional unobserved or hidden state vector S t , and the sequence of S t can be generated using a first-order Markov transition process (Rangel et al., 2004; Liang and Kelemen, 2007; Wu, 2008; Kojima et al., 2009; Wu et al., 2011) . The joint probability of {Y t , S t }:
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where P(S 1 ) is the probability of the first unobserved or hidden states and can be assumed to be generated from conjugate distributions such as multivariate normal or multivariate student t-distributions. P(S t |S t-1 ) is transition density or probability of hidden or unobserved states (e.g. genes that are not measured/included in the study), and it can be defined in the stochastic evolution equations as:
where g t is the deterministic transition function determining P(S t |S t-1 ) with Markov transition process. Let P(Y t |S t ) be the observation density or probability that is defined in the observation equations as:
where f t is the statistical transition function of the observation processes, and can be either linear or nonlinear function. W t , V t represent the random noise or errors following either Gaussian/multivariate normal distribution or non-Gaussian distributions. In a simple case, the transition functions of stochastic and observation equations take linear forms, while the distributions of the hidden states S t and the observation variables Y t are assumed to follow Gaussian distributions, then models (1-3) are specified as follows:
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where g = 1, …, P (number of genes), t = 1, …, T (number of time points). The hidden state values with S t,g = (S t,1 , …, S t,P )′ are the series-g specific n × 1 state vector, while S t = (S t,1 , …, S t,P )′ is n × P matrix and can be defined by a first-order Markov transition process representing the evolving time course of hidden states. G t is n × n state transition matrix for the temporal transition relationships of the hidden states of genes, and could be modeled, e.g. by the first order vector auto-regressive model. The observed gene expression data
g is a scale factor, and W t V t are n × n variance matrices. Since the observations are often divided into a set of input (or exogenous) variables and a set of output (response) variables (Beal et al., 2005) . Including inputs in both the state equation and observation equation, the model (4) are further modified as follows:
where U t,g is the input observation vector with dimension of n × 1. Q t is P × n input to the state matrix and H t is P × n input to the observation matrix. Since we are particularly interested in modeling the effects of the influence of the expression of one gene at a previous time point on another gene, its associated hidden state variables, and the gene-time-gene interactions, Therefore, we take U t,g = Y t-1,g , in which the input is replaced by the previous time step output. Thus model (5) is further simplified:
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where (F′G) t is the hidden state dynamic matrix with the influence of hidden state variables on gene expression level at each time point. (F′Q′+H′) t contains both the gene-to-gene interaction and the gene-to-gene interactions "through" the hidden state over time, and is used to infer and estimate the temporal structure of genetic network or regulations. In a special case, G, Q, F, H are assumed time-invariant matrices in the univariate state space model setting, and ε t is the univariate noise with mean 0 and variance of σ 2 g (Rangel et al., 2004; Beal et al., 2005; Liang and Kelemen, 2007) .
Hierarchical Bayesian multivariate state space models and Monte Carlo Markov chain with Gibbs sampling for posterior inference
Note that univariate model (6) could be extended to multivariate models in order to describe patterns of dependency among multiple gene time courses, and discover the gene dependences of the underlying processes measured simultaneously on a common system (Liang and Kelemen, 2007) . Therefore, we propose multivariate state space model for learning gene correlations and their temporal behavior, and for constructing the dynamic genetic networks. Since microarray experiments are more concerned about the short-term prediction given the short-term gene time course data, and uneven observational time point gene measurements may involve more variability from time to time, the introduction of time variability in the multivariate model is advisable (Congdon, 2002; Storey, 2003) . This way, it not only produces good fit in the sampling period, but also has a good generalization performance. The time varying multivariate state space model is formulated as follows: for a P × 1 observational vector:
where each gene depends on both its own past (either hidden state or observed) and the past values of the other genes. Therefore the variations in expression for a given gene over time can be predicted by a small set of other genes. Moreover, simultaneously modeling several time courses gene expressions with model (7) has advantages of pooling information from related genes to improve the precision and out of sample predictions. However, as the number of genes and the presence of unobserved hidden states increase in the multivariate state space model, the high dimensionality for the coefficient matrices and gene-gene interactions may cause over-fitting issues and ill-posed solutions (Yoshida et al., 2005; Lèbre et al., 2010) . We propose the fully hierarchical Bayesian setting with hyper-inverse Wishart distributions to induce sparsity structure in the timevarying matrices in (7). For instance, the conjugate prior distribution is assumed with multivariate normal distribution:
is symmetric positive definite n × P matrix with elements Ω t = (ω t,1 , …, ω t,P ), which equivalently generated from Wishart distribution (Carvalho et al., 2007b; Mitsakakis et al., 2011; Wang and Li, 2012; Danaher et al., 2013; Lehermeier et al., 2013) . The advantage of using precision matrix instead of covariance matrix is that the latter is simpler to write but running in MCMC very slow. ρ t > 2 is the degrees of freedom, R t is P × P symmetric positive definite scale matrices (Carvalho and West, 2007; Carvalho et al., 2007a; Peterson et al., 2014) . Note that the prior distribution of multivariate normal assumption could be modified into conjugate multivariate t-distribution and the hyper-prior with inverse Gamma distribution, which is heavier tailed and thus more robust for noisy expression data (Finegold and Drton, 2014) .
The merits of above hierarchical Bayesian approaches compared with traditional non Bayesian state space models (Yoshida et al., 2005; Osamu et al., 2008; Lèbre et al., 2010) is that it allows treatment of general dynamic multivariate models with special shrinkage and regularization techniques for high dimension reduction, over-fitting and ill-posed issues. The fully Bayesian approach not only accounts for the uncertainty resulting from the error and noise terms (e.g. Σ t ) in the parameter estimation via credible intervals for the significance, but also the hyper-parameters (e.g. R t ), state vectors and associated dynamic changes are also estimated through the hierarchically constructed priors and the integration of all the parameters for dynamic network structure estimations (e.g. (F′Q′+H′) t ). Moreover, it makes the simulation-based approach [such as Monte Carlo Markov Chain (MCMC) with Gibbs sampling] easier compared with traditional MLE or EM approaches for parameter estimation and latent factor filtering (Carlin et al., 1992; Carter and Kohn; Kitagawa, 1996; Grzegorczyk and Husmeier, 2012; Wang and Li, 2012; Lehermeier et al., 2013) . MCMC with Gibbs sampling are utilized to approximate this integration by sampling from the fully Bayesian posterior distributions of all unknown quantities including the model parameters, the state variables and associated dynamic changes in order to estimate the network correlations for inferring the gene dependence structures and interactions (e.g. (F′Q′+H′) t ). MCMC with Gibbs sampling also allows us to examine the robustness of the inference with respect to choices for the priors and hyper-priors through simulation and sensitivity analysis.
Peterson et al. and a few others (Carvalho and West, 2007; Carvalho et al., 2007a,b; Carvalho and Scott, 2009; Mitsakakis et al., 2011; Wang and Li, 2012; Lehermeier et al., 2013; Peterson et al., 2014) have provided detailed MCMC for G-Wishart distributions in Gaussian graphical models settings. We utilized similar sampling procedures in our hierarchical Bayesian multivariate state space model for network constructions. Specifically, in MCMC Gibbs sampling, Gaussian approximations centered on the posterior models are implemented. The construction of the Gibbs sampler is drawing samples from the full conditional distributions of state variables and model parameters using proposed models conditional on the observed Y t . In the hierarchical Bayesian setting, prior and hyper prior distributions are assigned to these parameters and state variables based on conjugacy so that the full conditional distributions have closed forms (e.g. conjugate multivariate normal distribution with inverse Wishart distribution). Starting from an arbitrary set of initial values and conjugate priors and hyper priors, samples are drawn from the conditional distributions sequentially. When the Gibbs sampler run large enough so that the posterior distribution is not influenced by the initial values and distributions, e.g. 2000 samples after 6000 "burn-ins" are used for computations of the posterior means as the point estimate and 95% credible interval of a parameter or state variable. Note that the proposed models treat the irregularly time spaced gene expression data with missing/hidden/unobserved observations. Gibbs sampler has advantage of flexibly handling those through the full conditional distributions with only slight adjustments at the time points of missing data or hidden states. Moreover, we used over-relaxation methods to aid the convergence and reduce the chance of local maxima. The estimated state variables and associated dynamic (including hidden states) together with the estimated covariance matrix are used to construct the dynamic genetic network (e.g. converted and standardized the estimated covariance matrices into correlation coefficients to measure the strengths and directions of the associated network structures).
In order to choose the best model for genetic network construction, the model selection criteria, such as the Akaike information criterion (AIC) or the Bayesian information criterion (BIC) or Bayes factors can be considered (Osamu et al., 2008) . The advantage of using statistical criteria like AIC or BIC over using sequential tests for model selection is that there is an asymptotic equivalence between cross-validation (split the data into training, validation, and testing) and AIC/BIC (Stone, 1974) . However, AIC is useful for nonnested models, it works poorly in the cases of random effects, multicollinearity and ill-conditioned matrices (Spiegelhalter et al., 2002; Carvalho and Scott, 2009) , which is typical for short time course gene expression data. It also has drawbacks of tending to be biased for complex models such as hierarchical models due to the fact that log-likelihood increases faster than the model complexity component. DIC is a measure proposed by Spiegelhalter et al. (2002) for model complexity and goodness of fit under the hierarchical Bayesian setting. It is more appropriate when comparing complex hierarchical models in the Bayesian setting, where the number of parameters is not clearly defined. One advantage is its inclusion of a prior distribution, which induces a dependency between parameters that is likely to reduce the effective dimensionality. Furthermore, it helps the prior models' identifications. DIC can be summarized by the posterior expectation of the deviance and complexity (effective number of parameters) as the expected deviance minus deviance at the posterior expectation of the parameters. We use DIC for model selections, comparisons and sensitivity analysis (e.g. prior specifications), which have been implemented in MCMC setting with WINBUGS (Lunn et al., 2000 (Lunn et al., , 2013 Congdon, 2005) .
Simulation analyses and application to the multiple tissue data for dynamic genetic network constructions
To examine and test the validity of the proposed models and assess their sensitivities to various priors and hyper-priors for best model structures, we first conduct simulation studies to ensure that the estimations of parameters, state variables, the dynamic changes and correlation structures are accurate, close to the observed real data, and are representative of actual interactions. To mimic the real observed gene expression data, we generate "time course gene expression data with 16 unevenly spaced time points" with the data format similar to our real gene expression data from liver tissue (measured with uneven time points: 0.25, 0.5, 0.75, 1, 2, 4, 5, 5. 5, 6, 7, 8, 12, 18, 30, 48 , and 72 h) (Liang and Kelemen, 2007 , 2008 ). For each simulated time course gene expression profile (t = 1, 2, …, 16), six biological gene replicates/samples (g = 1, …, 6) are randomly generated form normal/Gaussian distributions with mean zero and various variances/precision matrices (based on the known variances from real observed expression liver data) for the noise/error terms at each time point. This simulated data set is applied to our proposed models (6) and (7) with various conjugate prior distributions, hyper-priors, and initial values for model comparisons and selections to find the best model structures using DIC. For instance, model (6), the univariate state space model, the special case G, Q, F, H are assumed as time-invariant matrices with prior distributions of univariate normal with mean zero and errors with variances that were varied from 0.001 to 0.5. To make the MCMC simulation with Gibbs sampling for posterior distributions of all unknown quantities including state variables and parameters easier, rather than assume the prior distributions of the coefficient matrices G, Q, F, H and errors/noises following normal assumptions separately, we assume, e.g. (F′G) t,g~N (0, 0.001),(F′Q′+H′) t,g~N (0, 0.001) , g = 1, …, 6, t = 1, …, 16. To ensure that it is sampling from its equilibrium distribution, 2000 samples after 6000 burn-in are used for computations of the posterior distributions of parameters and state variables and for drawing inferences for 95% credible intervals of the parameters and state variables (Grzegorczyk and Husmeier, 2012) . The computed model selection criteria DIC value for this model setting is fairly large (6.502E+7) and the deviance is 1230.0 indicating the model complexity (effective number of parameters, posterior expectation of the parameters) is not effectively reduced with this model. This may due to the univariate normal state space model (6) assuming genes are not correlated, or "strong prior data conflict or estimated posterior is very non-normal" (Spiegelhalter et al., 2002) . Therefore, we conclude that the model (6) is not a good model.
To improve the above model, we further apply the simulated data to the multivariate state space model (7) with inclusion of the conjugate prior distributions of the correlation covariance matrix and hyper-inverse Wishart distributions for inducing sparsity model structure in the constrained matrices. To do so, we extend above prior distributions from univariate normal distribution to multivariate normal distributions with mean still zero, while the hyper-parameters of the matrix Σ were generated from an inverse Wishart distribution:
, the hyper-prior distribution for (ρ, R) is specified, e.g. with the degree of freedom is six, and the hyper prior scale matrix of precision R are specified as 
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The DIC for this model is fairly small (463.9) compared with previous model, and the number of parameters estimated in this model is 294 which indicates a better model with decent model fit. Next, to examine the potential issue of "strong prior data conflict or non-normal," we further modify the prior distribution of multivariate normal model into multivariate t-distribution (which is heavier tailed and thus more robust), and the hyper-prior with inverse Gamma distribution with various initial values (e.g. 0.001). We are able to achieve a significantly smaller DIC value of 195.1 indicating even better model. This may be due to the robustness of multivariate t-distribution for gene expression data, and it may generate future observations in the time course encompassing the true model (Spiegelhalter et al., 2014) .
The best model structure obtained from the above simulation analysis is then applied to three tissues (kidney, liver and muscle) gene expression data, and the genes significantly differentially expressed in response to CS drugs that are identified from our earlier studies (Liang and Kelemen, 2007 , 2008 . Table 1 shows the estimated six commonly differentially expressed gene expressions from three tissues using multivariate Bayesian state space model. The significant differentially expressed genes are marked with *, and are determined based on the estimated credible interval not including 0 from Bayesian state space model. Figure 1 displays their dynamic changes responding to therapeutic doses, including the observed, the estimated gene expressions using hierarchical Bayesian multivariate state space model. The estimated hidden state variables that are not measured but estimated through our models in the time course gene expression are also included in the same figure. We can visualize that the estimated dynamic changes to therapeutic doses from six genes that differentially expressed commonly in three tissues (kidney, liver, and muscle) that are very similar and close to our observed/measured gene expressions, which indicates that dynamic changes of expressions were well captured and predicted through the proposed model. Note that for the time points (0.25, 0.5, 1, 2, 4 h), gene expressions are observed and measured directly from experiments, and modeled through statistical/observation model part (see red dotted line in Figure 1 ). They are unevenly spaced time points, and the distances between these known time points are increased and varied from 0.5-0.25 = 0.25, 1-0.5 = 0.5, 2-1 = 1, 4-2 = 2 and so forth; while the time points 0.75, 1.25, 1.5, 1.75, etc. are unseen or unobserved, which are treated as hidden states and are modeled in the stochastic equation. Together with the observed gene expression, these unobserved or unseen time points of the gene expression time course data are retreated and considered as evenly distributed, and are estimated through our proposed multivariate state space model (see Figure 1 the estimated blue lines).
We conducted gene-gene interaction dynamic network analysis using the proposed models by examining the six commonly differentially expressed genes from three-tissues (liver, muscle, kidney), which were identified from our earlier studies (Liang and Kelemen, 2007 , 2008 . The estimation of the precision/ scale matrix for the covariance of six significant genes is: 
The non-zero values of non-diagonals of the covariance indicate the existence of interactions between these six genes. Gene-gene interaction from time to time (time varied) obtained from our model is shown in Table 2 . The estimated covariance matrix is converted and standardized into correlation coefficients for constructions of the genetic networks. Since these preselected genes have been confirmed from earlier study that are differentially expressed among the tissues, it is known that the genetic effect on the disease outcome or treatment is relatively small, but with many small effects accumulated together to contribute to Table 1 : Gene expression profiles from Bayesian state-space model from six genes that differentially expressed commonly in three tissues (kidney, liver and muscle).
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U05989_at Gene3517 the outcome. Therefore, we choose less stringent criteria for the estimated correlation coefficients (e.g. 0.1) to be included in the time varied gene-gene interactions and dynamic network constructions, all the correlation coefficients that were greater than 0.10 (or less than -0.10) were highlighted and included. Figure 2 displays the results of the constructed gene-time-gene interaction network for six studied genes that are significantly differentially expressed at five time points from three-tissues (liver, muscle, kidney). To further validate our approach and model, we expanded the number of genes from six differentially expressed from three-tissues to 44, which are commonly differentially expressed genes in two tissues (liver and muscle), the best fitted model with smallest DIC value resulted from simulation studies were applied to these 44 Figure 1: The estimated dynamic changes to therapeutic doses from six genes that differentially expressed commonly in three tissues (kidney, liver, and muscle).
genes for genetic network constructions. Figure 3 shows the constructed interaction network from these commonly differentially expressed genes in both liver and muscle. Results from either six differentially expressed from three-tissues or the 44 commonly differentially expressed genes in two tissues data sets show that the genomic dynamic changes and interaction network in response to CS drug treatment can be well captured by our proposed models.
To further evaluate and validate these constructed dynamic genetic networks, we conduct function and gene-mediated pathway analysis and compare with published work (Hazra et al., 2008; Yao et al., 2008; Jin et al., 2003; Fang et al., 2011; Nguyen et al., 2014) . It is notable that the interactive genes are dominated and activated in metabolic pathways in liver (oxidative phosphorylation, pentose phosphate pathway, and purine metabolism), and in signaling pathways dominated in muscle (insulin signaling, MAPK signaling, neurotrophin signaling, PPAR signaling, and Wnt signaling). These significant interactions might be related GRE, glucocorticoid receptor (GR), TFs, and be more likely to be important as CSs responsive functions either taking place in a tissue-specific manner in one of the two tissues or commonly activated in both liver and muscle tissues during MPL infusion (Nguyen et al., 2014) . These dynamic gene expression networks include both direct and indirectly correlated expressions and their changes over time, which may explain in addition to direct regulation through GRE binding sites in the 5′ regulatory regions of genes, there are changes in expression that are the indirect results of CSs because of changes in expression of TFs that act as secondary biosignals directly or indirectly modulating the transcription of genes. This may explain why drug effects remain strong even after the down-regulation of GR mRNA to the point of almost being eliminated. For instance, the genes affected by CSs include both immunosuppressive genes, mostly associated with therapeutic effects, and metabolic genes often associated with adverse effects whose regulation is mainly controlled by GR through gene-mediated pathways.
Discussion
Various pharmacodynamics and pharmaco-genomic modeling have been presented for the dynamic changes of CSs in rats from genomic perspective (Hazra et al., 2008; Fang et al., 2011; Jusko, 2013; Nguyen et al., 2014) . It is important to further improve the understanding of the gene-gene interactions, the direct and indirect interplays, and the time-dependence at a systematic level caused by CS therapy in order to potentially discover the precise genes that may be the most critical in producing favorable therapeutic outcomes (Jin et al., 2003; Yao et al., 2008) . Building efficient computational methods including various structural learning techniques for learning dynamic genetic network structure, correlations and pathways are challenging, but important aspects in pursuit of personalized and precision medicine today (Akutsu et al., 2000; Segal et al., 2003; Segul et al., 2003; Shannon et al., 2003; Marbach et al., 2009) . In this paper, we proposed and applied multivariate state space models for constructing gene-time-gene interaction networks through explicit model specification in the fully hierarchical Bayesian setting (e.g. estimation of multivariate covariance and precision matrix). The proposed models are applied to multiple tissues (liver, skeletal muscle, and kidney) Affymetrix gene expression time course data sets following CS drug administration. Results show that the proposed models can infer the hidden and un-measurable variables/factors that affect observed gene expressions, and can analyze and predict time course gene expression data not measured at fixed time intervals (Table 1 , Figure 1 ). The flexibility of modeling the expression measurements as continuous, rather than discrete and therefore with dynamic systems rather than unrealistic static models is one major advantage. Moreover, the proposed hierarchical Bayesian multivariate state space models provide us the uncertainty estimates of all parameters through credible intervals for the dynamic changes and correlations among the genes, through counting the time dependence of expressions in the transitional covariance matrix which could be used for detecting sparse dynamic network with shrinkage/regulation estimations and for differentially expressed genetic pathway discovery (Figures 2 and 3) . Note that the most existing computational tools for pathway or genetic network analysis only provide the information of either genes correlated or not (Jin et al., 2003) , or focus on estimating the kinetic parameters (Hazra et al., 2008; Fang et al., 2011; Nguyen et al., 2014) , few directly measure or estimate the strength/magnitude and direction of the correlations with uncertainty in the given pathway or network. This is another merit of our proposed dynamic hierarchical Bayesian state space modeling approaches. In addition, the proposed models can be applied to the estimate of drug effects of various diseases where non-standard distributions, non-stationary and nonlinear features with short unevenly spaced gene expressions are measured. The proposed model also have great potential for learning the dynamic and more complex biological and medical systems as a whole, and may help us to better understand system-wide dynamics/changes and errors of pharmacological and medical agents and their genetic and environmental modifiers.
Due to its multivariate dynamic probabilistic features, the proposed state space based approaches could be expanded to other large scale genomic data, such as next generation sequence (NGS) combined with real time electronic health record (EHR) for more comprehensive and robust systematic and network based analysis in order to transform the newly available big biomedical data into predictions and diagnostics for precision medicine and personalized healthcare with better decision making and patient outcomes. To do so, modified multivariate hierarchical Bayesian state space frameworks with proper assignments of the prior and hyper-prior distributions for the state and hidden variables, transition probability or matrix need to be placed in order to achieve efficient shrinkage and regulation effects for such high dimensional data. Another important extension of our current work is to overcome the computational limitations of slow convergence problems of MCMC algorithms by using reversible jump MetropolisHastings algorithm or newly developed hybrid adaptive MCMC algorithm such as Markov-modulated Poisson processes (Rao and Teh, 2013) . In this way, we can speed up inferring the medium to large size interaction networks that may incorporate other environmental covariates for more interpretable results. Moreover, the recently developed other prior distributions, such as double exponential priors, spike and slab priors with Markov random field, non-conjugate Dirichlet process algorithms, new model selection criterion such as Bayesian predictive information criterion (BPIC), and multi-scale network inference algorithms with multi-scale performance scores for handling higher-order network structures could be explored and compared for learning the robustness of modeling the large dynamic genomic network relatedness structure and complex multivariate biological systems from a predictive view point (Akutsu et al., 2000; Lunn et al., 2000; Spiegelhalter et al., 2002; Segal et al., 2003; Segul et al., 2003; Shannon et al., 2003; Ando, 2007; Carvalho and Scott, 2009; Marbach et al., 2009; Finegold and Drton, 2014; Oates et al., 2014; Spiegelhalter et al., 2014) .
